We have just achieved our goal of developing the world’s best working genome editing platform.
TargetGene’s patent has recently been granted in the US following grants in Israel, Australia, New Zealand, Ukraine, Russia, and China. We now hold some of the most valuable IP in the field, and are ready to develop in the therapeutics arena. For TargetGene the time is perfect, and competing technologies have paved the way forward in the market.
TargetGene has attracted three corporate strategic investors from its inception.
“…There aren’t many technologies that come along that can truly be called game changers. Gene editing, though, fits the description. Less than 5% of monogenic diseases have approved treatments. Many of the biotechs that do have approved drugs for treating these genetic diseases generate billions of dollars in revenue each year… the potential profits for investors willing to take on the risks are huge. There’s also a chance that even better approaches for gene editing are developed, making CRISPR, ZFN, and TALEN obsolete…“
Join us on our way to the top!